Neurocrine Biosciences (NBIX) Stock Overview
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for NBIX from our risk checks.
NBIX Community Fair Values
Create NarrativeSee what 80 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Neurocrine Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$131.67 |
| 52 Week High | US$160.18 |
| 52 Week Low | US$105.45 |
| Beta | 0.35 |
| 1 Month Change | -0.053% |
| 3 Month Change | -3.23% |
| 1 Year Change | 23.53% |
| 3 Year Change | 37.39% |
| 5 Year Change | 47.23% |
| Change since IPO | 953.36% |
Recent News & Updates
Recent updates
NBIX: Future Upside Will Hinge On Tardive Dyskinesia Franchise Execution
The updated analyst price target for Neurocrine Biosciences increases to $186.45 from $178.04. Analysts attribute the change to more supportive long-term earnings expectations and higher assumed future P/E multiples, even as they refine revenue growth and margin assumptions.
NBIX: Mixed 2026 Guidance And Policy Risks Will Shape Future Returns
Analysts have made a small upward adjustment to the fair value estimate for Neurocrine Biosciences to about $140.54, reflecting updated price targets that weigh mixed revisions across the Street against generally constructive views on Ingrezza and Crenessity. Analyst Commentary Street research around Neurocrine Biosciences has been active, with a mix of supportive views on key assets like Ingrezza and Crenessity and a series of price target tweaks that pull in different directions.NBIX: Future Upside Will Depend On Crenessity Adoption And Pipeline Progress
Analysts have trimmed the blended price target for Neurocrine Biosciences slightly to about $178, reflecting modest tweaks to growth, discount rate and P/E assumptions, while incorporating mixed but generally constructive views on Ingrezza and Crenessity uptake from recent research updates. Analyst Commentary Street research on Neurocrine Biosciences has been active, with several firms adjusting price targets and models around recent earnings, updated guidance and new information on Ingrezza and Crenessity.NBIX: 2026 Guidance Execution And CAH Competition Will Shape Future Returns
Analysts have kept the fair value estimate for Neurocrine Biosciences steady at $140, while revising their models slightly to reflect updated revenue growth, margins, and P/E assumptions following recent earnings, guidance, and a mix of modest price target cuts and a fresh $160 Outperform initiation. Analyst Commentary Across recent research, you are seeing a mix of optimism around the pipeline and commercial assets along with a cluster of more cautious valuation resets.NBIX: Execution On 2026 Guidance And Competitive CAH Data Will Shape Outlook
Neurocrine Biosciences' updated analyst price target of $140.00, down from $169.00, reflects refreshed models after Q4 results and 2026 guidance, with analysts still pointing to Ingrezza and Crenessity as key drivers in their long term assumptions despite recent target trims across the Street. Analyst Commentary Street research around Neurocrine Biosciences has turned more mixed, with several bearish analysts trimming price targets following Q4 results and updated 2026 guidance, while a few others have made only modest upward adjustments.Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting
Feb 12NBIX: Future Returns Will Hinge On Crenessity Execution And Pipeline Delivery
Analysts made a modest trim to their Neurocrine Biosciences price targets, generally landing around the high US$170s. Updated models reflect slightly more conservative revenue growth assumptions and a marginally higher discount rate, partly offset by steady margin expectations and supportive views on Crenessity and Ingrezza.
NBIX: Future Revenue Will Depend On Execution Across Two Key Franchises
Analysts have raised their fair value estimate for Neurocrine Biosciences to about US$204 from US$192. This reflects updated assumptions that include slightly stronger revenue growth, higher profit margins and a lower future P/E multiple after recent Street research refined expectations for Ingrezza, Crenessity and competitor dynamics.NBIX: Commercial Execution And Pipeline Progress Will Drive Future Shareholder Returns
Analysts have raised their fair value estimate for Neurocrine Biosciences from about $177.92 to $179.66, reflecting updated models that incorporate recent price target revisions, current product performance, and expectations regarding future competition and commercial execution. Analyst Commentary Recent research updates show a mix of optimism and caution around Neurocrine Biosciences, with most price target moves clustering around the high $160s to mid $180s and reflecting updated models on current products, competitive developments in congenital adrenal hyperplasia, and spending to support commercial execution.NBIX: Advancing CNS Pipeline Readouts Will Drive Future Shareholder Returns
Analysts have modestly increased their average price target for Neurocrine Biosciences by about $3, to roughly $178, citing stronger than expected product performance, sustained Ingrezza growth momentum, and growing confidence in the company’s advancing pipeline despite potential IRA related pricing headwinds. Analyst Commentary Street research remains broadly constructive on Neurocrine, with multiple firms nudging price targets higher as they factor in stronger execution, commercial visibility for Ingrezza and Crenessity, and a maturing late stage pipeline.NBIX: Late-Stage CNS Pipeline Readouts Will Drive Future Shareholder Value
Analysts have nudged their blended price target for Neurocrine Biosciences modestly higher to the high $170s to low $180s range, reflecting stronger than expected Ingrezza and Crenessity performance, confidence in commercial execution ahead of IRA related headwinds, and growing optimism around the longer term pipeline. Analyst Commentary Bullish analysts largely frame the recent pullback as a mismatch between robust fundamentals and short term market sentiment, with multiple firms lifting price targets into the mid $160s to mid $190s range even as shares consolidated.NBIX: Late-Stage Pipeline Advancements Will Drive Shareholder Value Amid Industry Headwinds
Neurocrine Biosciences' analyst price target has increased modestly, up by $3 to $174. Analysts cite ongoing strong commercial performance, expanded sales force initiatives, and a robust late-stage pipeline as supporting factors for sustained growth potential.NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value
The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.Analysts Boost Neurocrine Biosciences Price Target Citing Strong Revenue Outlook and Clinical Results
Analysts have raised their price target for Neurocrine Biosciences from $168.25 to $169.95. They cite stronger revenue outlooks for key products and supportive recent clinical trial data as the main reasons for this adjustment.Earnings Tell The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) As Its Stock Soars 27%
May 11
Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 07Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025
Apr 22Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity
Apr 16Neurocrine Biosciences revenue will grow by 10% with Crenessity and Ingrezza sales if they can maintain the retail price.
Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
Dec 18Shareholder Returns
| NBIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | -2.2% | 0.6% |
| 1Y | 23.5% | 30.4% | 28.7% |
Return vs Industry: NBIX underperformed the US Biotechs industry which returned 30.4% over the past year.
Return vs Market: NBIX underperformed the US Market which returned 28.7% over the past year.
Price Volatility
| NBIX volatility | |
|---|---|
| NBIX Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: NBIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NBIX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 2,000 | Kyle Gano | www.neurocrine.com |
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions.
Neurocrine Biosciences, Inc. Fundamentals Summary
| NBIX fundamental statistics | |
|---|---|
| Market cap | US$13.20b |
| Earnings (TTM) | US$478.60m |
| Revenue (TTM) | US$2.86b |
Is NBIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBIX income statement (TTM) | |
|---|---|
| Revenue | US$2.86b |
| Cost of Revenue | US$1.07b |
| Gross Profit | US$1.79b |
| Other Expenses | US$1.31b |
| Earnings | US$478.60m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 05, 2026
| Earnings per share (EPS) | 4.76 |
| Gross Margin | 62.67% |
| Net Profit Margin | 16.73% |
| Debt/Equity Ratio | 0% |
How did NBIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 14:38 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neurocrine Biosciences, Inc. is covered by 39 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Aydin Huseynov | Benchmark Company |